| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 4, 2024 | BioStock: Alligator’s mitazalimab data published in The Lancet Oncology | BioStock: Alligator’s mitazalimab data published in The Lancet Oncology
Tue, Jun 04, 2024 09:15 CET Report this content
Alligator Bioscience’s phase II data with cancer immunotherapy mitazalimab have been published in The Lancet Oncology – ... |
| May 2, 2024 | BioStock: Orion option exercise triggers milestone payment for Alligator | BioStock: Orion option exercise triggers milestone payment for Alligator
Thu, May 02, 2024 08:57 CET Report this content
The collaboration between Alligator Bioscience and the global pharma company Orion Corporation continues to bear fruit.... |
| Apr 2, 2024 | BioStock: Alligator Bioscience on the importance of prolonging life | BioStock: Alligator Bioscience on the importance of prolonging life
Tue, Apr 02, 2024 08:15 CET Report this content
What does time mean to a person who's cancer might not be cured? Prolonged life can bring hope for alternative treatments, o... |
| Mar 21, 2024 | BioStock: Alligator’s CEO on current development and the rights issue | BioStock: Alligator’s CEO on current development and the rights issue
Thu, Mar 21, 2024 09:13 CET Report this content
The recent phase II success with mitazalimab means that Alligator Bioscience can now start preparing for phase III. Beside... |
| Mar 14, 2024 | BioStock: Clinical effects observed with Alligator’s 4-1BB agonist | BioStock: Clinical effects observed with Alligator’s 4-1BB agonist
Thu, Mar 14, 2024 10:41 CET Report this content
Through its partnership with the US-based biotech Aptevo Therapeutics, Alligator Bioscience is evaluating the bispecific anti... |
| May 4, 2023 | BioStock Investor Pitch: Alligator Bioscience | BioStock Investor Pitch: Alligator Bioscience
Thu, May 04, 2023 08:55 CET Report this content
Alligator Bioscience has been off to a hot start in 2023. First came the positive interim results from the phase II study in pancreatic cancer. Th... |
| Jul 12, 2022 | Alligator Bioscience AB reports H1 2022 and Q2 2022 financial results and provides a business update | Alligator Bioscience AB reports H1 2022 and Q2 2022 financial results and provides a business update
Tue, Jul 12, 2022 08:00 CET Report this content
Mitazalimab OPTIMIZE-1 interim data and ATOR-1017 Phase 1 on track to readout in H2 2022
De... |
| May 31, 2022 | Alligator Bioscience to Present Additional data of ATOR-1017 First-in-Human Study via poster presentation at ASCO Annual Meeting 2022 | Alligator Bioscience to Present Additional data of ATOR-1017 First-in-Human Study via poster presentation at ASCO Annual Meeting 2022
Tue, May 31, 2022 08:00 CET Report this content
ATOR-1017 demonstrates an excellent clinical profile as a ... |
| May 9, 2022 | Alligator Bioscience expands its Board of Directors with the appointment of Staffan Encrantz and Denise Goode | Alligator Bioscience expands its Board of Directors with the appointment of Staffan Encrantz and Denise Goode
Mon, May 09, 2022 11:42 CET Report this content
Lund, Sweden, May 9, 2022 - Alligator Bioscience (Nasdaq Stockholm: ATORX) today a... |
| May 5, 2022 | Bulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2022 | Bulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2022
Thu, May 05, 2022 11:30 CET Report this content
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the ... |
| Apr 27, 2022 | Alligator Bioscience AB: Interim report January–March 2022 | Alligator Bioscience AB: Interim report January–March 2022
Wed, Apr 27, 2022 08:00 CET Report this content
A Quarter of Advancements for Alligator’s Key Assets
“Q1 2022 was marked by many important advancements. We made progress with our ke... |
| Apr 5, 2022 | Notice of annual general meeting in Alligator Bioscience AB | Notice of annual general meeting in Alligator Bioscience AB
Tue, Apr 05, 2022 08:30 CET Report this content
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, th... |
| Apr 1, 2022 | Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences | Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences
Fri, Apr 01, 2022 08:07 CET Report this content
Lund, Sweden, April 1, 2022 – Alligator Bioscienc... |
| Mar 23, 2022 | Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg | Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg
Wed, Mar 23, 2022 08:33 CET Report this content
Lund, Sweden, March 23, 2022 – Alligator Bioscience (Nasd... |
| Mar 22, 2022 | Alligator Bioscience publishes Annual Report for 2021 | Alligator Bioscience publishes Annual Report for 2021
Tue, Mar 22, 2022 10:30 CET Report this content
Lund, Sweden, March 22, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2021 has been pub... |
| Feb 11, 2022 | Alligator Bioscience AB: Year End report January-December 2021 | OPTIMIZE-1 Phase II - On Track and Moving Forward
"During the fourth quarter 2021, Alligator reached several key milestones in our pre-clinical, clinical, and partnered programs. Our priorities continue to be shaped by the rising need ... |
| Feb 11, 2022 | Alligator Bioscience AB: Year End report January–December 2021 | Alligator Bioscience AB: Year End report January–December 2021
Fri, Feb 11, 2022 08:00 CET Report this content
OPTIMIZE-1 Phase II – On Track and Moving Forward
“During the fourth quarter 2021, Alligator reached several key milestones in ou... |
| Jan 18, 2022 | Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported | Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported Tue, Jan 18, 2022 08:00 CET
Lund, Sweden, January 18, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an updat... |
| Dec 16, 2021 | Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability Data | Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability Data Thu, Dec 16, 2021 08:00 CET
Lund, Sweden, December 16, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) to... |
| Dec 16, 2021 | Last day of trading in paid subscription shares (Sw. BTA) in Alligator | Last day of trading in paid subscription shares (Sw. BTA) in Alligator Thu, Dec 16, 2021 19:00 CET
Alligator Bioscience AB (publ)’s ("Alligator" or the “Company") rights issue has now been registered with the Swedish Companie... |
| Dec 2, 2021 | Alligator carries out a directed issue of shares to guarantors in connection with the completed rights issue | Alligator carries out a directed issue of shares to guarantors in connection with the completed rights issue Thu, Dec 02, 2021 21:00 CET
Alligator Bioscience AB (publ) ("Alligator" or the "Company") has completed the rig... |
| Dec 1, 2021 | Alligator announces final outcome of rights issue | Alligator Bioscience AB (publ) ("Alligator" or the "Company") announces that the Company's rights issue of shares (the "Rights Issue"), in which the subscription period ended on 26 November 2021, has been compl... |
| Dec 1, 2021 | Alligator announces final outcome of rights issue | Alligator announces final outcome of rights issue Wed, Dec 01, 2021 08:30 CET
Alligator Bioscience AB (publ) ("Alligator" or the "Company") announces that the Company’s rights issue of shares (the “Rights Issue”), in whi... |
| Nov 29, 2021 | Alligator announces preliminary outcome of rights issue | Alligator announces preliminary outcome of rights issue Mon, Nov 29, 2021 08:32 CET
rights issue of shares (the “Rights Issue”) ended on 26 November 2021. The preliminary outcome shows that the Rights Issue has been oversubscribed. Through ... |
| Nov 29, 2021 | Alligator announces preliminary outcome of rights issue | rights issue of shares (the "Rights Issue") ended on 26 November 2021. The preliminary outcome shows that the Rights Issue has been oversubscribed. Through the Rights Issue, Alligator will receive approximately SEK 257 million bef... |
| Nov 12, 2021 | Alligator Announces Poster Presentation on OPTIMIZE-1 at SITC Virtual Annual Meeting 2021 | Alligator Announces Poster Presentation on OPTIMIZE-1 at SITC Virtual Annual Meeting 2021 Fri, Nov 12, 2021 08:30 CET
Poster presentation to highlight the design of Optimize-1, evaluating mitazalimab in combination with chemotherapy in pati... |
| Nov 12, 2021 | Alligator Announces Poster Presentation on ATOR-1017 at SITC Virtual Annual Meeting 2021 | Alligator Announces Poster Presentation on ATOR-1017 at SITC Virtual Annual Meeting 2021 Fri, Nov 12, 2021 08:59 CET
Poster presentation to highlight the ability of ATOR-1017 to activate and rescue tumor infiltrating exhausted T cells in sy... |
| Nov 12, 2021 | The subscription period in Alligator Bioscience's rights issue begins today | Today is the first day of the subscription period in Alligator Bioscience AB (publ)'s ("Alligator" or the "Company") rights issue of shares (the "Rights Issue") which was resolved by the Board of Directors on 7... |
| Nov 12, 2021 | Alligator Announces Poster Presentation on Neo-X-Prime™ presenting data on the lead compound targeting CD40 and CEA at SITC Virtual Annual Meeting 2021 | Alligator Announces Poster Presentation on Neo-X-Prime™ presenting data on the lead compound targeting CD40 and CEA at SITC Virtual Annual Meeting 2021 Fri, Nov 12, 2021 08:50 CET
Poster Presentation to highlight our Neo-X-Prime™ platform t... |
| Nov 12, 2021 | The subscription period in Alligator Bioscience's rights issue begins today | The subscription period in Alligator Bioscience's rights issue begins today Fri, Nov 12, 2021 08:00 CET
Today is the first day of the subscription period in Alligator Bioscience AB (publ)'s ("Alligator" or the "Company")... |
| Nov 9, 2021 | Alligator Bioscience publishes prospectus in connection with forthcoming rights issue | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN... |
| Nov 9, 2021 | Alligator Bioscience publishes prospectus in connection with forthcoming rights issue | Alligator Bioscience publishes prospectus in connection with forthcoming rights issue Tue, Nov 09, 2021 16:45 CET
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CAN... |
| Oct 22, 2021 | Alligator Bioscience : enters into agreements on subscription commitments with board members and senior executives | The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or "the Company") has previously, subject to approval by the Extraordinary General Meeting on 8 November 2021, resolved to carry out a rights issue of... |
| Oct 21, 2021 | Alligator Bioscience AB: Interim report January-September 2021 | First Patient Dosed in Optimize-1 Phase II
"We continued to make great strides in the third quarter of 2021. The first patient was dosed in OPTIMIZE-1, our clinical Phase II study, that will assess the effect of mitazalimab in first li... |
| Oct 21, 2021 | Alligator Bioscience AB: Interim report January–September 2021 | Alligator Bioscience AB: Interim report January–September 2021 Thu, Oct 21, 2021 08:00 CET
First Patient Dosed in Optimize-1 Phase II
“We continued to make great strides in the third quarter of 2021. The first patient was dosed in OPTIMIZE-... |
| Oct 21, 2021 | Alligator Announces First Patient Dosed in Phase II Clinical Trial with Shanghai Henlius Biotech, Inc. & AbClon, Inc. | Lund, Sweden, October 20, 2021 - Alligator Bioscience AB ("Alligator" or the "Company") today announced that the Company was notified that the first patient has been dosed in its Phase II clinical trial collaboration wit... |
| Oct 21, 2021 | Alligator Bioscience AB: Interim report January–September 2021 | First Patient Dosed in Optimize-1 Phase II
"We continued to make great strides in the third quarter of 2021. The first patient was dosed in OPTIMIZE-1, our clinical Phase II study, that will assess the effect of mitazalimab in first li... |
| Oct 21, 2021 | Alligator Announces First Patient Dosed in Phase II Clinical Trial with Shanghai Henlius Biotech, Inc. & AbClon, Inc. | Alligator Announces First Patient Dosed in Phase II Clinical Trial with Shanghai Henlius Biotech, Inc. & AbClon, Inc. Thu, Oct 21, 2021 07:45 CET
Lund, Sweden, October 20, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) to... |
| Sep 22, 2021 | Alligator Bioscience : to Participate in Upcoming Investor Conferences | Lund, Sweden, September 23, 2021 - Alligator Bioscience AB ("Alligator" or the "Company") today announces that Søren Bregenholt, Chief Executive Officer, will participate and host one-on-one investor meetings at the foll... |
| Jul 13, 2021 | Alligator Bioscience AB: Interim report January–June 2021 | Alligator Bioscience AB: Interim report January–June 2021 Tue, Jul 13, 2021 08:00 CET
Positive Phase I data for ATOR-1017
”As new CEO of Alligator Bioscience, after just around a month, let me say that my high expectations on the company ha... |
| Apr 5, 2021 | ALLIGATOR BIOSCIENCE AB (PUBL)
Alligator Bioscience : postpones the Annual General Meeting to June 1, 2021 | Lund, Sweden - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the board of directors has decided to postpone the Annual General Meeting to June 1, 2021, in connection with that Soren Bregenholt takes office as new CEO o... |
| Apr 3, 2021 | ALLIGATOR BIOSCIENCE AB (PUBL)
Alligator Bioscience : postpones the Annual General Meeting to June 1, 2021 | Lund, Sweden, April 3, 2021 - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the board of directors has decided to postpone the Annual General Meeting to June 1, 2021, in connection with that Søren Bregenholt takes offi... |
